Evidence map›Paper›PMID 41526750›Full record

ArticleDoklady. Biochemistry and biophysics2025

Low-Dose MLN4924 Enhances SH-SY5Y Cell Viability and Migration by Targeting SOCS3 Signaling.

Zelin Lai, Simin Yang, Xia Liu, Zhili Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zelin LaiNeurosurgery Center, National Key Clinical Specialty, Engineering Research Center of Diagnostic and Therapeutic Technology and Devices for Cerebrovascular Diseases in Ministry of Education, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital Institute for Brain Science and Intelligence, Zhujiang Hospital, Southern Medical University, 510282, Guangzhou, China. laizelin@smu.edu.cn.
Simin YangNeurosurgery Center, National Key Clinical Specialty, Engineering Research Center of Diagnostic and Therapeutic Technology and Devices for Cerebrovascular Diseases in Ministry of Education, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital Institute for Brain Science and Intelligence, Zhujiang Hospital, Southern Medical University, 510282, Guangzhou, China.
Xia LiuNeurosurgery Center, National Key Clinical Specialty, Engineering Research Center of Diagnostic and Therapeutic Technology and Devices for Cerebrovascular Diseases in Ministry of Education, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Zhujiang Hospital Institute for Brain Science and Intelligence, Zhujiang Hospital, Southern Medical University, 510282, Guangzhou, China.
Zhili LiuSongjiang Research Institute, Shanghai Key Laboratory of Emotions and Affective Disorders, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China. liuzhili19@mails.ucas.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MLN4924 (pevonedistat), a selective inhibitor of the NEDD8-activating enzyme, has inhibitory effects on various tumors by blockade of the neddylation pathway. Conversely, recent studies show that low-dose MLN4924 exerts pro-survival effects in both cancer cells and neurons, however, its actions on SH-SY5Y cells remain unclear. In this study, the effects of low-dose MLN4924 in SH-SY5Y cells were assessed by CCK-8 and Transwell assay, respectively. SH-SY5Y cells were transfected with enhanced green fluorescent protein plasmid to further observe neurite changes. The expression of SOCS3, p-JAK2 and p-STAT3 were analyzed by Western blot, and the potential interaction between MLN4924 and SOCS3 was explored via in silico molecular docking. Our results showed that 0.1 μM MLN4924 significantly enhanced SH-SY5Y cell viability and migration while concurrently reducing neurite outgrowth. The expression level of SOCS3 was significantly increased in the MLN4924 treatment group compared with the control group, but the phosphorylation levels of JAK2 and STAT3 showed no changes. Molecular docking further predicted that Glu63 of SOCS3 serves as a key residue for MLN4924 binding. Together, low-dose MLN4924 enhances SH-SY5Y cell viability and migration by targeting SOCS3 signaling, independent of JAK2/STAT3 signaling.

Indexed as

Cell MovementCell SurvivalCyclopentanesPyrimidinesSignal TransductionSuppressor of Cytokine Signaling 3 ProteinCell Line, TumorHumansJanus Kinase 2Molecular Docking SimulationSTAT3 Transcription FactorCyclopentanesJAK2 protein, humanJanus Kinase 2pevonedistatPyrimidinesSOCS3 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorSuppressor of Cytokine Signaling 3 Proteincell migrationcell viabilityMLN4924SH-SY5Y cellsSOCS3

Identifiers

PMID41526750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.